Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01659827 · ClinicalTrials.gov registry record · NA

Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis

A NA study of Plantar Fasciitis, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
45
Enrollment target
2
Study locations

NCT01659827: Completed NA study of Plantar Fasciitis, sponsored by MiMedx Group.

NCT01659827 is a NA study of Plantar Fasciitis that has completed, run by MiMedx Group. The registered enrollment target is 45 participants, below the 102-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01659827, a NA study of Plantar Fasciitis, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.

Conditions Studied

Interventions

  • OTHER Saline
  • OTHER Marcaine
  • OTHER 0.5cc AmnioFix
  • OTHER 1.25cc AmnioFix

Study Locations (2)

Virginia

  • Professional Education and Research Institute - Roanoke
  • Professional Education and Research Institute - Salem

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2012-09
Est. Completion 2013-03
Phase NA
MiMedx Group

32 total trials

What the finished NCT01659827 record still lists

NCT01659827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 102-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Plantar Fasciitis appearing as the primary indexed condition, and to 4 interventions - of which Saline is the first listed.

NCT01659827 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT01659827 about?

NCT01659827 is a clinical study titled "Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis". The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.

What is the current status of trial NCT01659827?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2012-09. Estimated completion is 2013-03.

What conditions does trial NCT01659827 study?

This clinical trial studies the following conditions: Plantar Fasciitis.

What interventions are being tested in trial NCT01659827?

The interventions under investigation include: Saline (OTHER), Marcaine (OTHER), 0.5cc AmnioFix (OTHER), 1.25cc AmnioFix (OTHER).

Who is sponsoring clinical trial NCT01659827?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01659827 being conducted?

This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plantar Fasciitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01659827, the US trial registry maintained by the National Library of Medicine. NCT01659827 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.